UPJOHN (THAILAND) CO., LTD.

UPJOHN (THAILAND) CO., LTD. functions as the local affiliate of a global pharmaceutical manufacturer. It is not a standalone pure trader; rather, it represents the manufacturing parent company's commercial, marketing, and distribution operations in Thailand.

Company Introduction:

UPJOHN (THAILAND) CO., LTD. was the Thai subsidiary of The Upjohn Company, a long-established American pharmaceutical manufacturer. In the context of global pharmaceutical restructuring, the Upjohn brand and its portfolio of established medicines ultimately became part of Viatris Inc. In Thailand, UPJOHN (THAILAND) CO., LTD. (or its successor entities under the Viatris umbrella) is primarily responsible for the marketing, sales, distribution, and regulatory management of a broad range of pharmaceutical products. These products address various therapeutic areas, serving the healthcare needs of the Thai market. The company manages the commercial aspects and supply chain logistics for its portfolio, ensuring the availability of essential medicines to patients and healthcare providers in Thailand.

The UPJOHN (THAILAND) CO., LTD. was a subsidiary of Pfizer's Upjohn division, which later combined with Mylan to form Viatris. Its product portfolio, focusing largely on Established Medicines and non-communicable diseases (NCDs), included globally recognized brands such as:

* **LIPITOR** (atorvastatin calcium) for cholesterol reduction

* **CELEBREX** (celecoxib) for pain and inflammation (e.g., arthritis)

* **VIAGRA** (sildenafil) for erectile dysfunction

* **ZOLOFT** (sertraline) for depression and anxiety

* **DILANTIN** (phenytoin) for seizures

* **LYRICA** (pregabalin) for neuropathic pain and other conditions

* **DEPO-PROVERA** (medroxyprogesterone acetate) injectable contraceptive (historically an Upjohn product, marketed globally)

* **GELFOAM** (absorbable gelatin sponge) for hemostasis in surgery (historically an Upjohn product)

The company's focus in Thailand was on serving patients with NCDs using this existing portfolio of drugs.